Biotech

All Articles

Roche throws out $120M tau possibility, giving back rights to UCB

.Roche has returned the legal rights to UCB's anti-tau antibody bepranemab, ignoring a $120 million ...

Editas strengthens in vivo technique by means of $238M Genenvant deal

.Editas Medicines has signed a $238 million biobucks contract to combine Genevant Science's crowd na...

Combo outcomes, Vicodin overlook as well as outstanding protection

.Vertex has actually mentioned period 3 data on its own near-approval ache drug prospect suzetrigine...

Angelini pens $360M biobucks contract for ph. 1 human brain condition medication

.Italy's Angelini Pharma has authorized a $360 million biobucks contract fixated a stage 1-stage bra...

Sage gives up fifty percent of R&ampD staff and also agitates C-suite once again

.Sage Rehabs' latest effort to diminish its pipe as well as staff will view a third of the biotech's...

With period 1 record, Atmosphere possesses an eye on early-stage sac cancer

.With its lead applicant in a phase 3 trial for an unusual eye cancer, Feeling Biosciences is hoping...

Less than a year in, BenevolentAI chief executive officer is actually out-- Chutes &amp Ladders

.Invite to this week's Chutes &amp Ladders, our roundup of notable management hirings, shootings and...

Roche MAGE-A4 trial withdrawn after critical assessment

.Roche has actually produced yet another MAGE-A4 plan vanish, removing a stage 1 test of a T-cell bi...

FDA puts partial hang on BioNTech-OncoC4 stage 3 test

.The FDA has implemented a partial hold on a stage 3 non-small tissue lung cancer cells dry run thro...

REGiMMUNE, Kiji merge to produce Treg 'tremendously company,' program IPO

.Taiwan's REGiMMUNE and also Europe-based Kiji Rehabs are combining to generate an around the world ...